Literature DB >> 22954683

Patent controversies and court cases: cancer diagnosis, therapy and prevention.

Arsenio M Fialho1, Ananda M Chakrabarty.   

Abstract

Patents are issued essentially by all countries on inventions that are deemed novel, non-obvious, clearly described and of significant utility or industrial application. The only exceptions to patenting an invention are abstract ideas, laws of nature and natural phenomena, although the exceptions vary depending on countries where moral, public order or human rights considerations are also taken into account. Although patent laws are updated over decades, the rapid progress of science creates situations that the patent laws on the book cannot address, leading to contentious legal issues. This is often true for life saving drugs, particularly drugs for cancers or HIV/AIDS, which are expensive and beyond the reach of poor people because of the proprietary positions of these patented drugs. Another contentious issue is the patent eligibility of human genes and mutations that are often thought of nature's contribution to human health and propagation and should be beyond the reach of patentability. In this review, we address some of these current legal issues and their implications for the development of diagnostic methods, therapeutic interventions and even prevention for cancer, a scourge of mankind.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954683      PMCID: PMC3493429          DOI: 10.4161/cbt.21958

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  19 in total

1.  Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Authors:  Anita Chaudhari; Magdy Mahfouz; Arsenio M Fialho; Tohru Yamada; Ana Teresa Granja; Yonghua Zhu; Wataru Hashimoto; Beatrix Schlarb-Ridley; Wonhwa Cho; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Biochemistry       Date:  2007-01-24       Impact factor: 3.162

2.  A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.

Authors:  Rajeshwari R Mehta; Tohru Yamada; Brad N Taylor; Konstantin Christov; Marissa L King; Dibyen Majumdar; Fatima Lekmine; Chinnaswamy Tiruppathi; Anne Shilkaitis; Laura Bratescu; Albert Green; Craig W Beattie; Tapas K Das Gupta
Journal:  Angiogenesis       Date:  2011-06-11       Impact factor: 9.596

3.  Bioengineered bugs, drugs and contentious issues in patenting.

Authors:  Ananda M Chakrabarty
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

Review 4.  Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework.

Authors:  Benjamin S Avner; Arsenio M Fialho; Ananda M Chakrabarty
Journal:  Bioengineered       Date:  2012-07-03       Impact factor: 3.269

5.  Akt1 deletion prevents lung tumorigenesis by mutant K-ras.

Authors:  M C Hollander; C R Maier; E A Hobbs; A R Ashmore; R I Linnoila; P A Dennis
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

6.  Development of a novel mouse glioma model using lentiviral vectors.

Authors:  Tomotoshi Marumoto; Ayumu Tashiro; Dinorah Friedmann-Morvinski; Miriam Scadeng; Yasushi Soda; Fred H Gage; Inder M Verma
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

7.  Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer.

Authors:  Vasu Punj; Suchita Bhattacharyya; Djenann Saint-Dic; Chenthamarakshan Vasu; Elizabeth A Cunningham; Jewell Graves; Tohru Yamada; Andreas I Constantinou; Konstantin Christov; Bethany White; Gang Li; Dibyen Majumdar; Ananda M Chakrabarty; Tapas K Das Gupta
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

8.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

9.  Glioblastoma multiforme: novel therapeutic approaches.

Authors:  Arsenio M Fialho; Prabhakar Salunkhe; Sunil Manna; Sidharth Mahali; Ananda M Chakrabarty
Journal:  ISRN Neurol       Date:  2012-02-08

10.  A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

Authors:  M A Warso; J M Richards; D Mehta; K Christov; C Schaeffer; L Rae Bressler; T Yamada; D Majumdar; S A Kennedy; C W Beattie; T K Das Gupta
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

View more
  1 in total

Review 1.  Bacterial proteins and peptides in cancer therapy: today and tomorrow.

Authors:  Ananda M Chakrabarty; Nuno Bernardes; Arsenio M Fialho
Journal:  Bioengineered       Date:  2014-05-29       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.